Annexon (ANNX) Cash from Financing Activities (2019 - 2026)
Annexon (ANNX) posted quarterly Cash from Financing Activities of $32.9 million for Q1 2026, up 55655.93% year-over-year from N/an in Q1 2025, and down 65.4% quarter-over-quarter from $95.1 million in Q4 2025.
Annexon (ANNX) Cash from Financing Activities (2019 - 2026) Analysis & Trends
Annexon's Cash from Financing Activities history runs 8 years deep, the most recent figure standing at $32.9 million for Q1 2026.
- In Q1 2026, Cash from Financing Activities rose 55655.93% year-over-year to $32.9 million; the TTM figure through Mar 2026 stood at $141.7 million (up 9.96% YoY), while the FY2025 annual figure was $108.9 million, down 32.47% from the prior year.
- Cash from Financing Activities for Q1 2026 stood at $32.9 million, down from $95.1 million in the prior quarter.
- The five-year high for Cash from Financing Activities was $123.7 million in Q2 2024, with the low at $19000.0 in Q1 2022.
- The 5-year median for Cash from Financing Activities is $9.3 million (2024), against an average of $35.1 million.
- The sharpest annual moves came in 2022 and 2025: Cash from Financing Activities jumped 168138.36% in 2022, then sank 99.88% in 2025.
- Annexon's Cash from Financing Activities stood at $108000.0 in 2022, then jumped by 108787.04% to $117.6 million in 2023, then plunged by 95.78% to $5.0 million in 2024, then soared by 1814.21% to $95.1 million in 2025, then plunged by 65.4% to $32.9 million in 2026.
- Business Quant data shows ANNX's Cash from Financing Activities at $32.9 million in Q1 2026, $95.1 million in Q4 2025, and $13.6 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | -426.70 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -1.22 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.42 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | -6.05 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -207,909.22 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | -273.15 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 36.24 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 27.18 Mn |
| 10 | Annexon | 1.00 Bn | 1.00 Bn | - | 32.10 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 32.10 Mn |
| Jun 30, 2026 | 32.10 Mn |
| Mar 31, 2026 | 32.90 Mn |
| Mar 31, 2026 | 32.90 Mn |
| Dec 31, 2025 | 95.08 Mn |
| Dec 31, 2025 | 95.08 Mn |
| Sep 30, 2025 | 13.56 Mn |
| Sep 30, 2025 | 13.56 Mn |
| Jun 30, 2025 | 153,000.00 |
| Jun 30, 2025 | 153,000.00 |
| Mar 31, 2025 | 59,000.00 |
| Mar 31, 2025 | 59,000.00 |
| Dec 31, 2024 | 4.97 Mn |
| Dec 31, 2024 | 4.97 Mn |
| Sep 30, 2024 | 175,000.00 |
| Sep 30, 2024 | 175,000.00 |
| Jun 30, 2024 | 123.65 Mn |
| Jun 30, 2024 | 123.65 Mn |
| Mar 31, 2024 | 32.41 Mn |
| Mar 31, 2024 | 32.41 Mn |